Tecavir Special Precautions

Monitor liver function tests every 3 months, and viral and serological markers for hepatitis B every 3-6 months. Discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis. Recurrent hepatitis may occur on discontinuation.
Use in pregnancy: There are no adequate and well-controlled studies in pregnant women. Entecavir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Use in lactation: It is not known whether entecavir is excreted in human milk. Mothers should be instructed not to breastfeed if they are taking entecavir.
Use in children: Safety and effectiveness of entecavir in pediatric patients <16 years have not been established.
Use in the elderly: Entecavir is significantly excreted by the kidney and the risk of toxic reactions to Tecavir may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.